Skip to content

The Standard of Care: Building Your Treatment Strategy

Last updated:

The standard of care for Progressive Supranuclear Palsy (PSP) focuses on symptom management through a multidisciplinary team. Since traditional Parkinson's drugs like Levodopa often fail, physical, occupational, and speech therapy are crucial for maintaining mobility, safety, and quality of life.

Key Takeaways

  • Because there are no FDA-approved medications to reverse PSP, treatment focuses entirely on symptom management and improving quality of life.
  • Levodopa usually fails to treat PSP because the disease damages the brain's dopamine receivers, preventing effective signal transmission.
  • A multidisciplinary team of physical, speech, and occupational therapists is the most effective approach for managing daily PSP symptoms.
  • Targeted treatments like Botox injections can effectively manage specific symptoms such as excessive drooling or involuntary eye closing.
  • Clinical trials are currently investigating therapies like monoclonal antibodies and ASOs that target the abnormal tau protein causing PSP.

When you are diagnosed with Progressive Supranuclear Palsy (PSP), the focus of your medical care shifts. Because there are currently no FDA-approved medications that can stop or reverse the disease, the “standard of care” is centered entirely on symptom management and quality of life [1][2].

Think of your care not as a single pill, but as a team of experts working together to help you stay active, safe, and connected [3][4].

Why Parkinson’s Drugs Often Fail

Most patients with PSP are initially prescribed Levodopa, the gold-standard drug for Parkinson’s disease. However, in PSP, this medication usually has very limited or no effect [5][6].

  • The Difference: In Parkinson’s, the brain’s “receivers” for dopamine are still healthy. In PSP, the disease damages the “receivers” themselves (the postsynaptic system) in areas like the basal ganglia [5].
  • The Result: Because the receivers are damaged, adding more dopamine (Levodopa) doesn’t help the brain send signals effectively [5][6]. While some patients see a brief or modest improvement in stiffness, it typically does not help with balance or vision [7][8].

The Multidisciplinary Team: Your Most Powerful Tool

Since medication has limits, a multidisciplinary approach is the most effective way to manage PSP [3]. This team should include:

1. Physical Therapy (PT)

  • Focus: Balance, walking, and preventing falls [3].
  • Strategy: A therapist can teach you specific exercises to improve your stability and help you choose the right assistive devices (like a weighted walker) to keep you moving safely [3].

2. Speech-Language Pathology (SLP)

  • Focus: Swallowing (dysphagia) and communication [3].
  • Strategy: They can evaluate your swallowing safety to prevent pneumonia and provide tools or exercises to keep your voice clear and strong [3].

3. Occupational Therapy (OT)

  • Focus: Independence and home safety [3].
  • Strategy: An OT can suggest modifications to your home—like grab bars or specialized lighting—and help you find adaptive tools for eating, dressing, and hobbies [3].

Targeted Treatments for Specific Symptoms

While there is no “cure-all” drug, doctors can use specific treatments for certain bothersome symptoms:

  • Botulinum Toxin (Botox): Injections can be highly effective for treating excessive drooling (sialorrhea) or involuntary eye closing (blepharospasm) [9].
  • Mood & Sleep Support: Medications and therapy can address depression, anxiety, and daytime sleepiness, all of which significantly impact your quality of life [10].

The Search for a Cure

Scientists are actively researching disease-modifying therapies that target the tau protein directly [1]. Current trials are investigating:

  • Monoclonal Antibodies: Drugs that try to “soak up” or clear the toxic tau clumps [1][11].
  • Antisense Oligonucleotides (ASOs): Emerging therapies that aim to stop the brain from producing the abnormal tau protein in the first place [12].

While these treatments are not yet available for general use, participating in clinical trials is an option for many patients and helps move us closer to a future cure [1].

Return to the Main Guide

Frequently Asked Questions

Why doesn't Levodopa work well for Progressive Supranuclear Palsy?
In PSP, the disease damages the brain's dopamine receivers. Because these receivers are damaged, adding more dopamine through medications like Levodopa does not help the brain send signals effectively.
What role does physical therapy play in PSP treatment?
Physical therapy focuses on improving balance, walking, and preventing falls. A therapist can teach specific exercises for stability and help select the right assistive devices, like a weighted walker, to keep patients moving safely.
How can a speech-language pathologist help with PSP symptoms?
A speech-language pathologist evaluates swallowing safety to prevent complications like pneumonia, which is a common risk in PSP. They also provide specialized tools and exercises to help maintain clear communication as the disease progresses.
Can medication help with specific PSP symptoms like drooling?
Yes, targeted treatments like Botulinum Toxin (Botox) injections can be highly effective for managing bothersome symptoms such as excessive drooling or involuntary eye closing.
Are there any treatments being developed to cure PSP?
Scientists are actively researching disease-modifying therapies in clinical trials, including monoclonal antibodies and antisense oligonucleotides. These experimental treatments aim to target, clear, or prevent the abnormal tau protein clumps that cause the disease.

Questions for Your Doctor

  • Can we schedule a consult with a physical therapist who has specific experience with 'atypical' parkinsonism or balance disorders?
  • Since my response to Levodopa has been limited, are there any other medications we should consider for specific symptoms like drooling or muscle stiffness?
  • How can we involve a speech-language pathologist now to establish a baseline for my swallowing and communication?
  • Are there any open clinical trials for tau-targeting therapies or antisense oligonucleotides (ASOs) that I should consider?
  • Can you help us coordinate a 'multidisciplinary' care plan so that all my therapists and specialists are communicating with each other?

Questions for You

  • Which symptoms are currently interfering most with your daily joy or independence? (This helps your team prioritize treatment.)
  • Have you noticed any 'non-motor' issues like daytime sleepiness or feeling more depressed, which can also be addressed by your care team?
  • What are your primary goals for the next six months—staying active, improving communication, or making your home safer?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.

    Dunning EE, Decourt B, Zawia NH, et al.

    Neurology and therapy 2024; (13(4)):975-1013 doi:10.1007/s40120-024-00614-9.

    PMID: 38743312
  2. 2

    Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.

    Przewodowska D, Marzec W, Madetko N

    Frontiers in molecular neuroscience 2021; (14()):720220 doi:10.3389/fnmol.2021.720220.

    PMID: 34512258
  3. 3

    Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life.

    Fabbri M, Ledda C, Schirinzi T, et al.

    Parkinsonism & related disorders 2024; (125()):107047 doi:10.1016/j.parkreldis.2024.107047.

    PMID: 38964017
  4. 4

    Clinical Approach to Progressive Supranuclear Palsy.

    Ling H

    Journal of movement disorders 2016; (9(1)):3-13 doi:10.14802/jmd.15060.

    PMID: 26828211
  5. 5

    Autopallidotomy: From Colloquial Term to Scientific Theory.

    McCarter SJ, Savica R

    Journal of Parkinson's disease 2022; (12(7)):2009-2013 doi:10.3233/JPD-223491.

    PMID: 36120793
  6. 6

    Long-standing preservation of levodopa response in progressive supranuclear palsy.

    Sano T, Mizutani M, Ishihara T, et al.

    Journal of the neurological sciences 2024; (466()):123203 doi:10.1016/j.jns.2024.123203.

    PMID: 39260141
  7. 7

    Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

    Ye L, Sani SS, Veith Sanches L, et al.

    Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

    PMID: 39452005
  8. 8

    Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.

    Fernández-Ferreira R, García-Santos RA, Rodríguez-Violante M, et al.

    Revista espanola de geriatria y gerontologia 2019; (54(5)):251-256 doi:10.1016/j.regg.2019.04.002.

    PMID: 31324404
  9. 9

    Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.

    Cardoso F

    Toxicon : official journal of the International Society on Toxinology 2018; (147()):107-110 doi:10.1016/j.toxicon.2017.08.018.

    PMID: 28837826
  10. 10

    PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy.

    Li XY, Chen MJ, Liang XN, et al.

    Journal of Parkinson's disease 2023; (13(1)):83-91 doi:10.3233/JPD-223553.

    PMID: 36591660
  11. 11

    Emerging drugs for progressive supranuclear palsy.

    Giagkou N, Stamelou M

    Expert opinion on emerging drugs 2019; (24(2)):83-92 doi:10.1080/14728214.2019.1609450.

    PMID: 31007097
  12. 12

    How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?

    Lozupone M, Dibello V, Daniele A, et al.

    Expert opinion on pharmacotherapy 2024; (25(5)):571-584 doi:10.1080/14656566.2024.2345734.

    PMID: 38653731

This page provides educational information about Progressive Supranuclear Palsy (PSP) treatment and symptom management. It does not replace professional medical advice, diagnosis, or treatment from your neurologist or multidisciplinary care team.

Stay up to date

Get notified when new research about Progressive supranuclear palsy is published.

No spam. Unsubscribe anytime.